AIDS vaccine research in the stumble in the front row - an AIDS vaccine - the pharmaceutical industries
A scientific research to AIDS Vaccine researchers from the endless night to see a glimmer of hope: the United States and Thailand, researchers recently announced that they had developed a new type of test vaccine infected with the human body AIDS Reduce the risk of virus disease 31.2%. This is the 1983 discovery of HIV, the world's first effect of certain immune AIDS vaccine. While the immune effect is still very limited, but eventually realized the immune effect of a leap from scratch.
However, in the just-concluded 2009 World Conference on AIDS vaccine, as currently the world's only live vector vaccine clinical trials, carried out the research, the Chinese Centre for Disease Control and Prevention, AIDS experts SHAO chief said in a speech the first thing is that We are the technical route, and the United States and Thailand vaccine study were 20 years ago, Professor Hu Xiaoyue based on the work developed from. Unfortunately, that year, the "non-famous scientists," the view is not taken seriously. Otherwise, 10 years ago, we might get today's results.
20 years ago, the non-famous research scientist was ignored
In Baidu Type "Hu Yue AIDS" entries, one of the search results is No. 5 in 1993, the "Biology", which records the Chinese-American scientist Hu Yue research team at the time: "has been macaques successfully tested a vaccine to prevent AIDS. all subjects after the monkeys vaccinated immunity are greatly increased. acceptance of the vaccine will not be tested monkeys infected with HIV not only their own, and will not become a carrier of the virus ... ... "
In fact, as early as 1989, Hu music on in the paper, had no effect by the use of two separate vaccines form a "combined vaccine", which the first strains of pox virus in New York is responsible for doing initial free live vector to carry out HIV attacks the preparation; second proteins as a vaccine, "assists in hand." This "early to avoid - to strengthen" the idea was used in the United States and Thailand vaccine study design. However, Hu Yue was only medium-sized U.S. pharmaceutical company Bristol-Myers Squibb Chief Scientist of AIDS vaccine research, the results had not been the industry's attention.
That can influence the direction of the greatest scientists of academic theory of scientific thinking in accordance with, assume that the dead live vector carrier safety better than almost all the AIDS vaccine field to carry out a non-replicating vector-based vaccines and to death T cell immune-oriented research.
Lok Hu of the non-mainstream voices are drowned. In 1997, the United States, the money spent on Merck AIDS vaccine program started, use is non-replicative adenovirus vaccine died, however, plan to spend several hundred million dollars were suspended in 2007. Clinical trial results showed that the vaccine not only failed to protect, but observed in the vaccine group in more HIV virus Cases, people fall into the "AIDS vaccine will not have immunity effect" of disappointment.
Business seeks profit, makes the process of vaccine development setback again
The United States and Thailand were injected vaccine to the disappointment of a huge boost. But often accompanies bad news: the project by the U.S. military, the Thai Ministry of Public Health and other institutions was introduced in 2003, the United States National Institute of investors. Ironically, although "significant results" "historic breakthrough", "milestone" and praise pour into the vaccine, although it may have clinical value, but the vaccine has been used up! As before, as long do not see results, the production of the combined vaccine of two European companies, one has been discontinued, while another has closed down early.
Music of Hu also stop at the Bristol-Myers Squibb's economic considerations. 90's of last century, Hu Yue clinical study with the University of Washington scholar Cooperation , The vaccine advanced to Phase I clinical trial. But then he was forced to adjust the research, specializing in primate models mainly to the application of basic research. An important reason is that Bristol-Myers Squibb decided to terminate the AIDS vaccine project, focus on the development of AIDS drugs to make money.
I am writer, reports some information about sliding door operator , installing glueless laminate flooring.
